| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.060 | Biomarker | disease | BEFREE | Many drugs are now under investigations targeting different pathways critical for MPN development, such as the JAK-STAT (JAK2 inhibitors: INCB018424 or ruxolitinib, TG101348 or SAR302503, CYT387, SB1518, CEP701 and LY2784544) and the PI3K/AKT/mTOR (everolimus) pathways, or act through remodeling of chromatin with a key role in epigenetics (givinostat, panobinostat and vorinostat). | 22227528 | 2012 | ||||
|
0.060 | Biomarker | disease | BEFREE | Genetic disruption of SHP2 or treatment of oncogene-bearing cells with a novel SHP2 inhibitor alone or in combination with the PI3K inhibitor corrects MPD by disrupting a protein complex involving p85α, SHP2, and Gab2. | 22806893 | 2013 | ||||
|
0.060 | Biomarker | disease | BEFREE | In conclusion, combined inhibition of PI3K/mTOR and JAK2 signalling may represent a novel therapeutic strategy in MPN. | 24237791 | 2014 | ||||
|
0.060 | Biomarker | disease | BEFREE | Our data support the use of a combination of JAK2 and pan-class I PI3K inhibitors in the treatment of MPNs. | 24251790 | 2014 | ||||
|
0.060 | Biomarker | disease | BEFREE | Herein, we will review the clinically relevant inhibitors of the PI3K pathway that have been evaluated or hold promise for the treatment of Ph-ve MPNs. | 26062813 | 2016 | ||||
|
0.060 | AlteredExpression | disease | BEFREE | Molecular profiling of CD34+ cells and granulocytes of MPN determined gene expression patterns beyond their recognized function in disease pathogenesis that included dominant up-regulation of PI3K/AKT signaling. | 26275051 | 2016 |